Roger Mouawad

1.4k total citations
57 papers, 968 citations indexed

About

Roger Mouawad is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roger Mouawad has authored 57 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 19 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roger Mouawad's work include Angiogenesis and VEGF in Cancer (11 papers), Renal cell carcinoma treatment (10 papers) and Renal and related cancers (9 papers). Roger Mouawad is often cited by papers focused on Angiogenesis and VEGF in Cancer (11 papers), Renal cell carcinoma treatment (10 papers) and Renal and related cancers (9 papers). Roger Mouawad collaborates with scholars based in France, United States and China. Roger Mouawad's co-authors include David Khayat, D. Khayat, Claude Soubrane, Jean‐Philippe Spano, Olivier Rixe, Gabriel G. Malouf, Xiaoping Su, C. Soubrane, Judith Michels and Joël S. Bloch and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Roger Mouawad

53 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roger Mouawad France 21 523 308 208 177 155 57 968
Yvonne T.M. Tsang United States 18 533 1.0× 329 1.1× 166 0.8× 211 1.2× 141 0.9× 24 1.2k
Lidia Moserle Italy 18 647 1.2× 496 1.6× 173 0.8× 341 1.9× 111 0.7× 26 1.1k
Takayuki Mizoi Japan 17 404 0.8× 573 1.9× 365 1.8× 179 1.0× 141 0.9× 34 1.1k
Shunsuke Yanoma Japan 21 417 0.8× 503 1.6× 215 1.0× 323 1.8× 174 1.1× 53 1.2k
Satoru Shinriki Japan 24 850 1.6× 568 1.8× 214 1.0× 309 1.7× 102 0.7× 59 1.5k
Evelyn N. Garrett United States 10 461 0.9× 142 0.5× 205 1.0× 147 0.8× 97 0.6× 11 929
Ulrike Lacher Germany 10 631 1.2× 295 1.0× 109 0.5× 284 1.6× 88 0.6× 14 942
Masanobu Kusano Japan 15 897 1.7× 334 1.1× 119 0.6× 293 1.7× 157 1.0× 28 1.2k
Jianjun Yu China 13 455 0.9× 217 0.7× 113 0.5× 198 1.1× 276 1.8× 52 943
Takuji Mori Japan 16 513 1.0× 515 1.7× 245 1.2× 254 1.4× 181 1.2× 31 1.0k

Countries citing papers authored by Roger Mouawad

Since Specialization
Citations

This map shows the geographic impact of Roger Mouawad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Mouawad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Mouawad more than expected).

Fields of papers citing papers by Roger Mouawad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Mouawad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Mouawad. The network helps show where Roger Mouawad may publish in the future.

Co-authorship network of co-authors of Roger Mouawad

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Mouawad. A scholar is included among the top collaborators of Roger Mouawad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Mouawad. Roger Mouawad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Su, Xiaoping, Xiaofan Lu, Linda Dainese, et al.. (2023). Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors. Nature Communications. 14(1). 7884–7884. 9 indexed citations
3.
Malouf, Gabriel G., Xiaofan Lu, Roger Mouawad, et al.. (2022). Genetic landscape of indolent and aggressive Kaposi sarcomas. Journal of the European Academy of Dermatology and Venereology. 36(12). 2343–2351. 4 indexed citations
4.
Su, Xiaoping, Xiaofan Lu, Éva Compérat, et al.. (2021). Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome biology. 22(1). 7–7. 30 indexed citations
5.
Classe, Marion, Hui Yao, Roger Mouawad, et al.. (2018). Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny. Cell Reports. 25(3). 811–821.e5. 41 indexed citations
6.
Su, Xiaoping, Jianping Zhang, Roger Mouawad, et al.. (2017). NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. Cancer Research. 77(18). 4835–4845. 38 indexed citations
7.
Flippot, Ronan, Roger Mouawad, Morgan Rouprêt, et al.. (2017). Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Annals of Oncology. 28. v302–v303. 1 indexed citations
8.
Malouf, Gabriel G., Ronan Flippot, Roger Mouawad, et al.. (2017). Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup.. Journal of Clinical Oncology. 35(15_suppl). 4571–4571.
9.
Malouf, Gabriel G., Xiaoping Su, Jianping Zhang, et al.. (2016). DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clinical Cancer Research. 22(24). 6236–6246. 39 indexed citations
10.
Chaı̈bi, Pascal, et al.. (2011). Age-related changes in plasma levels of inflamatory and angiogenic cytokins in patients with cancer.. Journal of Clinical Oncology. 29(15_suppl). e19699–e19699. 2 indexed citations
11.
Spano, Jean‐Philippe, Yann Vano, Stéphane Vignot, et al.. (2011). GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Medical Oncology. 29(3). 1421–1428. 28 indexed citations
12.
Barète, Stéphane, Roger Mouawad, Sylvain Choquet, et al.. (2010). Skin Manifestations and Vascular Endothelial Growth Factor Levels in POEMS Syndrome. Archives of Dermatology. 146(6). 615–23. 40 indexed citations
13.
Mouawad, Roger, et al.. (2009). Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome. European Journal of Cancer. 45(8). 1407–1414. 40 indexed citations
14.
Soubrane, Claude, Olivier Rixe, Jean‐Baptiste Méric, David Khayat, & Roger Mouawad. (2005). Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Research. 15(3). 199–204. 35 indexed citations
15.
Mouawad, Roger, Jean-Philippe Spano, G Auclerc, et al.. (2005). Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy. Journal of Clinical Oncology. 23(16_suppl). 7540–7540. 1 indexed citations
16.
Mouawad, Roger, D. Khayat, & Claude Soubrane. (2000). Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Research. 10(5). 461–467. 35 indexed citations
17.
Mouawad, Roger, Éric-Charles Antoine, David Khayat, & Claude Soubrane. (2000). Effect of Endogenous Interleukin-6 on Fas (APO-1/CD95) Receptor Expression in Advanced Melanoma Patients. PubMed. 6(3). 135–140. 8 indexed citations
18.
Soubrane, Claude, et al.. (2000). A comparative study of Fas and Fas-ligand expression during melanoma progression. British Journal of Dermatology. 143(2). 307–312. 45 indexed citations
19.
20.
Mouawad, Roger, Olivier Rixe, A. Benhammouda, et al.. (1994). Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clinical & Experimental Immunology. 97(3). 342–346. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yvonne T.M. Tsang Breakdown of academic impact, for papers by Lidia Moserle Breakdown of academic impact, for papers by Takayuki Mizoi Breakdown of academic impact, for papers by Shunsuke Yanoma Breakdown of academic impact, for papers by Satoru Shinriki Breakdown of academic impact, for papers by Evelyn N. Garrett Breakdown of academic impact, for papers by Ulrike Lacher Breakdown of academic impact, for papers by Masanobu Kusano Breakdown of academic impact, for papers by Jianjun Yu Breakdown of academic impact, for papers by Takuji Mori
Rankless by CCL
2026